For example, testing of engineered HER2-specific CAR-T cells (T cells engineered with a chimeric antigen receptor) showed both regression and elimination of HER2-positive CRC tumors in a PDX model and subsequently protected mice from tumor re-challenge [74], as well as exploitation of combinatorial immunotherapies, several of which are currently under clinical evaluation [75]. Here, ERBB2 is linked to neoplasm.